Treatment of non-small-cell lung cancer in older persons

Michele Basche, Karen Kelly

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The majority of individuals diSagnosed with lung cancer in the United States are 70 years of age and older. Defining appropriate therapy for older patients with non-small-celllung cancer(NSCLC) is becoming a major focus of clinical research. In this article, we review the available data on clinical predictors of risk and benefit for elderly NSCLC patients receiving treatment via a variety of modalities, including surgery, radiotherapy, combined radiotherapy and chemotherapy, and chemotherapy alone. The data demonstrate that subgroups of elderly patients benefit from appropriately selected treatment. Participation of older patients in clinical trials designed to assess efficacy, toxicity, and quality-of-life outcomes for recently developed treatment modalities in this population is critical.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalOncology
Volume17
Issue number1
StatePublished - Jan 2003
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Patient Participation
Drug Therapy
Therapeutics
Lung Neoplasms
Neoplasms
Quality of Life
Clinical Trials
Research
Population

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Treatment of non-small-cell lung cancer in older persons. / Basche, Michele; Kelly, Karen.

In: Oncology, Vol. 17, No. 1, 01.2003, p. 31-39.

Research output: Contribution to journalArticle

Basche, Michele ; Kelly, Karen. / Treatment of non-small-cell lung cancer in older persons. In: Oncology. 2003 ; Vol. 17, No. 1. pp. 31-39.
@article{617b26c0c8f14840b666b16774be77ca,
title = "Treatment of non-small-cell lung cancer in older persons",
abstract = "The majority of individuals diSagnosed with lung cancer in the United States are 70 years of age and older. Defining appropriate therapy for older patients with non-small-celllung cancer(NSCLC) is becoming a major focus of clinical research. In this article, we review the available data on clinical predictors of risk and benefit for elderly NSCLC patients receiving treatment via a variety of modalities, including surgery, radiotherapy, combined radiotherapy and chemotherapy, and chemotherapy alone. The data demonstrate that subgroups of elderly patients benefit from appropriately selected treatment. Participation of older patients in clinical trials designed to assess efficacy, toxicity, and quality-of-life outcomes for recently developed treatment modalities in this population is critical.",
author = "Michele Basche and Karen Kelly",
year = "2003",
month = "1",
language = "English (US)",
volume = "17",
pages = "31--39",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "1",

}

TY - JOUR

T1 - Treatment of non-small-cell lung cancer in older persons

AU - Basche, Michele

AU - Kelly, Karen

PY - 2003/1

Y1 - 2003/1

N2 - The majority of individuals diSagnosed with lung cancer in the United States are 70 years of age and older. Defining appropriate therapy for older patients with non-small-celllung cancer(NSCLC) is becoming a major focus of clinical research. In this article, we review the available data on clinical predictors of risk and benefit for elderly NSCLC patients receiving treatment via a variety of modalities, including surgery, radiotherapy, combined radiotherapy and chemotherapy, and chemotherapy alone. The data demonstrate that subgroups of elderly patients benefit from appropriately selected treatment. Participation of older patients in clinical trials designed to assess efficacy, toxicity, and quality-of-life outcomes for recently developed treatment modalities in this population is critical.

AB - The majority of individuals diSagnosed with lung cancer in the United States are 70 years of age and older. Defining appropriate therapy for older patients with non-small-celllung cancer(NSCLC) is becoming a major focus of clinical research. In this article, we review the available data on clinical predictors of risk and benefit for elderly NSCLC patients receiving treatment via a variety of modalities, including surgery, radiotherapy, combined radiotherapy and chemotherapy, and chemotherapy alone. The data demonstrate that subgroups of elderly patients benefit from appropriately selected treatment. Participation of older patients in clinical trials designed to assess efficacy, toxicity, and quality-of-life outcomes for recently developed treatment modalities in this population is critical.

UR - http://www.scopus.com/inward/record.url?scp=0037266353&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037266353&partnerID=8YFLogxK

M3 - Article

C2 - 12599930

AN - SCOPUS:0037266353

VL - 17

SP - 31

EP - 39

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 1

ER -